-
Mashup Score: 2The White Coat Didn't Fit ― Until She Put on a Yellow Dress - 4 year(s) ago
After struggling to fit in to a residency program in the US, a Venezuelan-born doctor decided to suppress her personality and assume another, more acceptable identity.
Source: MedscapeCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0IL‐10 and TGF‐β cytokines decrease immune activation during normothermic ex vivo machine perfusion of the rat liver - 4 year(s) ago
Background Normothermic ex vivo liver perfusion (NEVLP) is a novel system for organ preservation which may improve over static cold storage (CS) clinically and offers the chance for graft modificati…
Source: AASLDCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0FDA Approval for Technetium Tc 99m Tilmanocept Expanded to Include Pediatric Patients - 4 year(s) ago
Technetium Tc 99m tilmanocept may now be used to enhance identification of lymph nodes in pediatric patients with certain tumors.
Source: Cancer NetworkCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0MWOY Madison 2021 - 4 year(s) ago
Help LLS – Upper Plains Region spread the word about MWOY Madison 2021!
Source: e.givesmart.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0UW begins new clinical trial to treat fatal blood diseases in children, young adults - 4 year(s) ago
The FDA-approved trial will use a form of transplant that replaces a patient’s bone marrow with alpha-beta T-cell depleted peripheral blood stem cells.
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors - 4 year(s) ago
Treatment of metastatic pediatric solid tumors remain a significant challenge, particularly in relapsed and refractory settings. Standard treatment has included surgical resection, radiation, chemotherapy, and, in the case of neuroblastoma, immunotherapy. Despite such intensive therapy, cancer recurrence is common, and most tumors become refractory to prior therapy, leaving patients with few…
Source: MDPICategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
The lab helps reduce the time it takes fledgling biohealth companies to launch by six to nine months and is instrumental in keeping biohealth talent in Wisconsin.
Source: news.wisc.eduCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Can Caloric Restriction Improve Chemotherapy Response in Overweight Patients With ALL? - ASH Clinical News - 4 year(s) ago
Can Caloric Restriction Improve Chemotherapy Response in Overweight Patients With ALL? – Acute Leukemias, Blood Advances in a Different Vein, From the Blood Journals, News – ASH Clinical News
Source: ASH Clinical NewsCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Cellular Therapies Hold Promise in Myeloid Malignancies – Acute Leukemias, Feature Articles, Spotlight – ASH Clinical News
Source: ASH Clinical NewsCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Universal CAR-T Platform Shows Promising Efficacy in Relapsed/Refractory AML - ASH Clinical News - 4 year(s) ago
Universal CAR-T Platform Shows Promising Efficacy in Relapsed/Refractory AML – Acute Leukemias, Literature Scan, News – ASH Clinical News
Source: ASH Clinical NewsCategories: Hem/Oncs, Latest HeadlinesTweet
I wish I was @ASCO watching @uwsmph Centennial Scholar @NarjustDumaMD talk about her experience as a physician in training. What a privilege to call her a colleague and friend @UWCarbone @uw_medicine and thank you for speaking about this @MedscapeOnc https://t.co/fu3eYQxprx